Abstract
Human clinical trials in type 1 diabetes (T1D) patients using mesenchymal stem cells (MSC) are presently underway without prior validation in a mouse model for the disease. In response to this void, we characterized bone marrow-derived murine MSC for their ability to modulate immune responses in the context of T1D, as represented in NOD mice. In comparison to NOD mice, BALB/c-MSC mice were found to express higher levels of the negative costimulatory molecule PD-L1 and to promote a shift toward Th2-like responses in treated NOD mice. In addition, transfer of MSC from resistant strains (i.e., nonobese resistant mice or BALB/c), but not from NOD mice, delayed the onset of diabetes when administered to prediabetic NOD mice. The number of BALB/c-MSC trafficking to the pancreatic lymph nodes of NOD mice was higher than in NOD mice provided autologous NODMSC. Administration of BALB/c-MSC temporarily resulted in reversal of hyperglycemia in 90% of NOD mice (p = 0.002). Transfer of autologous NOD-MSC imparted no such therapeutic benefit. We also noted soft tissue and visceral tumors in NODMSC-treated mice, which were uniquely observed in this setting (i.e., no tumors were present with BALB/c- or nonobese resistant mice-MSC transfer). The importance of this observation remains to be explored in humans, as inbred mice such as NOD may be more susceptible to tumor formation. These data provide important preclinical data supporting the basis for further development of allogeneic MSC-based therapies for T1D and, potentially, for other autoimmune disorders.
| Original language | English |
|---|---|
| Pages (from-to) | 993-1004 |
| Number of pages | 12 |
| Journal | Journal of Immunology |
| Volume | 183 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Jul 15 2009 |
Fingerprint
ASJC Scopus subject areas
- Immunology
- Medicine(all)
Cite this
Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes. / Fiorina, Paolo; Jurewicz, Mollie; Augello, Andrea; Vergani, Andrea; Dada, Shirine; La Rosa, Stefano; Selig, Martin; Godwin, Jonathan; Law, Kenneth; Placidi, Claudia; Smith, R. Neal; Capella, Carlo; Rodig, Scott; Adra, Chaker N.; Atkinson, Mark; Sayegh, Mohamed H.; Abdi, Reza.
In: Journal of Immunology, Vol. 183, No. 2, 15.07.2009, p. 993-1004.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes
AU - Fiorina, Paolo
AU - Jurewicz, Mollie
AU - Augello, Andrea
AU - Vergani, Andrea
AU - Dada, Shirine
AU - La Rosa, Stefano
AU - Selig, Martin
AU - Godwin, Jonathan
AU - Law, Kenneth
AU - Placidi, Claudia
AU - Smith, R. Neal
AU - Capella, Carlo
AU - Rodig, Scott
AU - Adra, Chaker N.
AU - Atkinson, Mark
AU - Sayegh, Mohamed H.
AU - Abdi, Reza
PY - 2009/7/15
Y1 - 2009/7/15
N2 - Human clinical trials in type 1 diabetes (T1D) patients using mesenchymal stem cells (MSC) are presently underway without prior validation in a mouse model for the disease. In response to this void, we characterized bone marrow-derived murine MSC for their ability to modulate immune responses in the context of T1D, as represented in NOD mice. In comparison to NOD mice, BALB/c-MSC mice were found to express higher levels of the negative costimulatory molecule PD-L1 and to promote a shift toward Th2-like responses in treated NOD mice. In addition, transfer of MSC from resistant strains (i.e., nonobese resistant mice or BALB/c), but not from NOD mice, delayed the onset of diabetes when administered to prediabetic NOD mice. The number of BALB/c-MSC trafficking to the pancreatic lymph nodes of NOD mice was higher than in NOD mice provided autologous NODMSC. Administration of BALB/c-MSC temporarily resulted in reversal of hyperglycemia in 90% of NOD mice (p = 0.002). Transfer of autologous NOD-MSC imparted no such therapeutic benefit. We also noted soft tissue and visceral tumors in NODMSC-treated mice, which were uniquely observed in this setting (i.e., no tumors were present with BALB/c- or nonobese resistant mice-MSC transfer). The importance of this observation remains to be explored in humans, as inbred mice such as NOD may be more susceptible to tumor formation. These data provide important preclinical data supporting the basis for further development of allogeneic MSC-based therapies for T1D and, potentially, for other autoimmune disorders.
AB - Human clinical trials in type 1 diabetes (T1D) patients using mesenchymal stem cells (MSC) are presently underway without prior validation in a mouse model for the disease. In response to this void, we characterized bone marrow-derived murine MSC for their ability to modulate immune responses in the context of T1D, as represented in NOD mice. In comparison to NOD mice, BALB/c-MSC mice were found to express higher levels of the negative costimulatory molecule PD-L1 and to promote a shift toward Th2-like responses in treated NOD mice. In addition, transfer of MSC from resistant strains (i.e., nonobese resistant mice or BALB/c), but not from NOD mice, delayed the onset of diabetes when administered to prediabetic NOD mice. The number of BALB/c-MSC trafficking to the pancreatic lymph nodes of NOD mice was higher than in NOD mice provided autologous NODMSC. Administration of BALB/c-MSC temporarily resulted in reversal of hyperglycemia in 90% of NOD mice (p = 0.002). Transfer of autologous NOD-MSC imparted no such therapeutic benefit. We also noted soft tissue and visceral tumors in NODMSC-treated mice, which were uniquely observed in this setting (i.e., no tumors were present with BALB/c- or nonobese resistant mice-MSC transfer). The importance of this observation remains to be explored in humans, as inbred mice such as NOD may be more susceptible to tumor formation. These data provide important preclinical data supporting the basis for further development of allogeneic MSC-based therapies for T1D and, potentially, for other autoimmune disorders.
UR - http://www.scopus.com/inward/record.url?scp=70249122431&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70249122431&partnerID=8YFLogxK
U2 - 10.4049/jimmunol.0900803
DO - 10.4049/jimmunol.0900803
M3 - Article
C2 - 19561093
AN - SCOPUS:70249122431
VL - 183
SP - 993
EP - 1004
JO - Journal of Immunology
JF - Journal of Immunology
SN - 0022-1767
IS - 2
ER -